Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions

Table 5 Recommended treatment regimens for hepatitis C virus GT3 infection

Recommendation category	Treatment option(s)	Treatment regimen
Preferred	SOF + DCV ± RBV	SOF + DCV for 12 wk (addition of RBV may be considered if cirrhosis has not been conclusively ruled out)
		In patients with compensated cirrhosis
		Treatment-naïve patients: SOF + DCV + RBV for 24 wk if patients can tolerate ribavirin well, if not SOF+DCV for 24 wk
		Treatment-experienced patients: SOF + DCV + RBV for 24 wk if patients tolerated ribavirin well, if not SOF + DCV for 24 wk
		In patients with decompensated cirrhosis:
		SOF + DCV + RBV for 12 wk
		If RBV is ineligible: SOF + DCV for 24 wk
Alternative	SOF + RBV	SOF + RBV for 24 wk (should be considered only when preferred regimens are not available)
	LDV + SOF + RBV	LDV + SOF + RBV for 12 wk (should be considered only when preferred regimens are not available)
Not recommended	Due to the advent of newer DAAs, pegylated interferon, boceprevir, and telaprevir-based regimens are not recommended.

DAAs: Direct-acting antivirals; DCV: Daclatasvir; LDV: Ledipasvir; RBV: Ribavirin; SOF: Sofosbuvir.